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Single-dose nevirapine (NVP) is effective in reducing mother-to-child transmission (MTCT) of HIV; however,
the subsequent development of drug resistance is problematic. The pharmacokinetic profile of the HIV entry
inhibitor maraviroc after a single intrapartum dose in rhesus macaques was studied to determine whether
maraviroc could serve as an alternative to NVP in a single-dose strategy. Four pregnant macaques received an
oral dose of maraviroc 2 h before delivery, and both infant and maternal plasma maraviroc concentrations and
CCR5 receptor occupancy on CD4 lymphocytes were measured over time. Maximum plasma maraviroc
concentrations were found at delivery (2-h-postintrapartum dose) in both the mothers and infants, with
median concentrations of 974 ng/ml (range, 86 to 2,830 ng/ml) and 22 ng/ml (range, 4 to 99 ng/ml), respectively.
Maraviroc was detected in the plasma of mothers up to 48 h after dosing but only as long as 3.5 h in the infants.
The median fetal-maternal area under the concentration-time curve (AUC) ratio was 0.009 (range, 0.000 to
0.015). Maraviroc receptor occupancy data showed evidence of unprotected CCR5 receptors on CD4 cells in
the mothers 24 to 48 h after dosing. Extremely low CCR5 expression on CD4 cells of newborn macaques
prevented determination of receptor occupancy in the infants. In rhesus macaques, maraviroc was poorly
transferred across the placenta and was quickly cleared from the infants’ blood. The low concentrations of fetal
maraviroc and short pharmacokinetic profile in infants suggest that a single maternal intrapartum dose of
maraviroc would not be effective in reducing the risk of MTCT of HIV.
Mother-to-child transmission (MTCT) is the second leading
mode of human immunodeficiency virus (HIV) transmission
worldwide, after heterosexual transmission (3). The prevalence
of MTCT is between 15 and 30% in non-breast-fed infants (10)
and between 30 and 45% in breast-fed infants (11, 30, 38).
MTCT prevalence is reduced to 2% in developed nations,
where women have access to suppressive combination antiretro-
viral regimens (15, 26). However, in resource-limited settings,
such as sub-Saharan Africa, the costs and logistics of using com-
bination antiretroviral therapy present a major challenge.
WHO guidelines recommend an antepartum, intrapartum,
and postpartum regimen of antiretroviral drugs to reduce the
risk of MTCT (4). However, in areas where care and infra-
structure are insufficient to deliver these regimens, the WHO
recommends, at minimum, administration of a single dose of
nevirapine (NVP) to the mother at the onset of labor and a
single dose to the infant after birth. This approach, although
suboptimal, has been shown to reduce MTCT by nearly 50%
(19). Unfortunately, the finding that up to half of women who
receive single-dose NVP develop overt resistance to the non-
nucleoside reverse transcriptase inhibitor (NNRTI) class (5,
14) has dampened enthusiasm for this simple and affordable
strategy. Subsequent studies have revealed even higher rates of
resistance when more sensitive methods of detection are used
(22). This outcome could lead to increased rates of transmitted
drug resistance and a reduced efficacy of subsequent NNRTI
regimens (23–24). While single-dose NVP is still the most
feasible option for many resource-poor settings, other single-
dose approaches of preventing MTCT, which do not jeopar-
dize future treatment options, are desperately needed.
Maraviroc is a CCR5 receptor antagonist approved to treat
HIV infection in adults as part of a combination regimen.
Maraviroc prevents HIV infection by blocking the binding of
HIV to the CCR5 coreceptor on the surface of the target host
cells (12, 37). Although some HIV strains can use alternative
coreceptors, transmission and early HIV infection are domi-
nated by CCR5-using strains (27, 32). Preventing infection of
the neonate by CCR5-using viruses during delivery could po-
tentially reduce the risk of MTCT. In addition, maraviroc has
a relatively high genetic barrier to the selection of resistance
(28), and being the only approved entry inhibitor, its intrapar-
tum use would be unlikely to undermine subsequent antiret-
roviral regimens used to treat the mother or infant.
The goal of this pilot study was to determine whether ma-
raviroc could efficiently cross the placenta in rhesus macaques
and have a suitable pharmacokinetic (PK) profile in neonates
to serve as a potential candidate for a single-dose intrapartum
strategy to prevent MTCT of HIV.
MATERIALS AND METHODS
Animals. Four pregnant macaques were selected from the type D retrovirus-
free and simian immunodeficiency virus (SIV)-free primate colony at the Cali-
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fornia Primate Center, University of California, Davis. Multiparous mothers
were selected for this study to decrease the risk of neglect of the infants post-
operatively. Animals were housed in accordance with the American Association
for Accreditation of Laboratory Animal Care standards and handled according
to the Guide for Care and Use of Laboratory Animals (20). When necessary,
animals were immobilized with intramuscular injection of 10 mg/kg of body
weight ketamine HCl (Parke-Davis, Morris Plains, NJ).
Intervention. Two hours prior to cesarean section, mothers received a single
oral dose of maraviroc (anhydrous; provided by Pfizer Inc., Groton, CT) dis-
solved in 15 ml 0.05 M citric acid buffer (pH 2.0) containing 10% ethanol by
intubation. Two mothers received 60 mg/kg, and 2 received 100 mg/kg. These
doses were near the highest that produced no observable adverse effects in
cynomolgus monkeys in preclinical toxicity studies (17). Infants were delivered by
cesarean section performed using inhalation anesthesia by a staff veterinarian
according to standard operating procedures. Blood was collected from the moth-
ers at 0, 1, 2, 4, 8, 24, and 48 h postdosing and from the infants at 4, 8, 24, and
48 h. Cord blood was used for the 2-h (at delivery) time point on the infants.
Follow-up blood samples were collected 1 and 2 weeks postdelivery.
Laboratory procedures. Plasma for PK analysis was isolated from EDTA-
anticoagulated whole blood by centrifugation at 800  g for 10 min and then
stored at 70°C. Amniotic fluid was also collected and stored at 70°C. Mara-
viroc concentrations in plasma and amniotic fluid were determined by high-
performance liquid chromatography–mass spectrometry (HPLC-MS) as previ-
ously described (7), with a lower limit of detection of 1 ng/ml and intra- and
interday variability of 10%. The peak and last serum concentrations of mara-
viroc (Cmax and Clast, respectively) and time required to reach Cmax and Clast
(Tmax and Tlast, respectively) were obtained directly by inspection of concentra-
tion-time profiles. The area under the concentration-time curve over 12 h
(AUC0–12) and total exposure [AUC(total)] were determined using the log-linear
trapezoidal rule (WinNonlin Professional, version 5.2.1; Pharsight Corp., Moun-
tain View, CA). CCR5 receptor occupancy on CD4 lymphocytes was deter-
mined by flow cytometry from whole blood using a MIP-1 ex vivo challenge
assay (16). Results were reported as the percentages of CCR5 receptors pro-
tected from internalization by MIP-1.
RESULTS
Plasma maraviroc concentrations over time in the 4 mother-
infant pairs are shown in Fig. 1, and the calculated PK values
are shown in Table 1. Maternal maraviroc plasma concentra-
tions were similar between the 60-mg/kg and 100-mg/kg doses,
except for a 10-fold-lower Cmax value for one animal that
received the higher 100-mg/kg dose. Overall, maternal Cmaxs
(median, 975 ng/ml; range, 86 to 2,830 ng/ml) were found at or
near delivery (median, 2 h postdose; range, 1 to 2 h). The
median half-life of maraviroc in the mothers was 14.1 h (range,
7.2 to 21.1 h). Maraviroc was still detectable in maternal
plasma 48 h after dosing but not in plasma collected after 1 and
2 weeks.
In the infants, maximal plasma maraviroc concentrations
(median, 22 ng/ml) were also found at delivery. However, in-
fant Cmaxs were a median of 44-fold lower (range, 21- to
55-fold) than the median mothers’ Cmax, and maraviroc was
undetectable in all infants by 48 h. The maraviroc half-life for
the infants could not be accurately calculated due to an insuf-
ficient number of time points with detectable drug. There was
a 68-fold-lower total AUC for the infants than for the mothers.
Amniotic fluid concentrations were 2- to 4-fold lower than that
of the corresponding cord blood for each infant.
CCR5 receptor occupancy data showed a profile similar to
the PK data for the mothers. Complete protection from inter-
nalization of CCR5 receptors on the surface of maternal CD4
lymphocytes following ex vivo MIP-1 challenge was found
FIG. 1. Plasma maraviroc concentrations of macaque mothers (closed circles) or their infants (open squares) over 48 h following a single
intrapartum dose of maraviroc (mothers for panels A and B received 60 mg/kg; mothers for panels C and D received 100 mg/kg). Mothers were
administered maraviroc at 0 h, and the infants were delivered at 2 h. The lower limit of detection of maraviroc was 1 ng/ml.
4060 WINTERS ET AL. ANTIMICROB. AGENTS CHEMOTHER.
during the first 8 h after maraviroc dosing, indicating complete
receptor occupancy. Partial protection was observed over 24 to
48 h, when a median of 65% of the maternal CCR5 receptors
(range, 54 to 77%) were protected from internalization, indi-
cating approximately 35% of receptors no longer had bound
maraviroc. There was a significant correlation between CCR5
receptor occupancy and plasma maraviroc concentrations
(r2  0.546; P  0.0001). However, by 1 week postdosing,
there was no evidence of protection of CCR5 receptors in the
mothers.
In the infants, attempts to measure CCR5 receptor occu-
pancy were complicated by the inherently extremely low ex-
pression of CCR5 receptors on newborn macaque CD4 lym-
phocytes. CCR5 expression ranged from 0 to 1% on infant
CD4 lymphocytes; the low number of analyzable events and
limitations on the amount of blood that could be collected
prevented accurate assessment of receptor internalization in
infant blood samples in the ex vivo assay.
DISCUSSION
The results of this study demonstrated that in rhesus ma-
caques, a single intrapartum maternal dose of maraviroc was
poorly transferred to the fetus. Plasma maraviroc concentra-
tions in the newborn macaques were less than 1% of the
mothers’ plasma concentrations. While the single intrapartum
doses used in this study (60 to 100 mg/kg) were 15- to 25-fold
higher than the standard human dose (300 mg, or 5 mg/kg), the
Cmax and AUC for the macaque mothers were similar to those
found for humans (1–2, 13). However, Cmax and AUC values
plateau above doses of 300 mg in humans (1), and thus, the
similar plasma concentrations found in the macaques were not
unexpected. The high maraviroc doses were designed to
achieve maximal concentrations in maternal blood, suitable for
assessing placental transfer into fetal compartments; however,
only low fetal levels were found.
MTCT of HIV is associated with high maternal viral loads
(8, 18, 26, 34, 36). Potent antiretroviral therapy that reduces or
suppresses maternal circulating HIV levels in advance of de-
livery has been shown to reduce the rate of MTCT to less than
1% (15, 21). In resource-poor settings, where access to HIV
diagnostic testing or potent ARV therapy is limited, adminis-
tration of a single intrapartum dose of NVP at delivery has
been shown to substantially reduce MTCT and is recom-
mended as a minimum intervention (4). However, previous
studies showed single-dose NVP (29) or AZT (34) adminis-
tered during labor did not significantly affect the maternal viral
load by the time of delivery, although reductions were mea-
sured at later time points. Thus, protection from intrapartum/
early-postpartum MTCT is likely due to a combination of re-
duction in the maternal breast milk viral load and provision of
prophylactic NVP concentrations to the newborn (9, 29, 31,
34). Pharmacologically, NVP reaches concentrations in new-
borns that are approximately 90% of maternal concentrations,
and it is detectable in newborn plasma for up to 1 week (25).
NVP has a low molecular mass (267 Da) and low protein
binding (30%), which are favorable characteristics of drugs
that efficiently cross the placenta (35). In contrast, maraviroc
has a high molecular mass (513 Da) and is approximately 76%
protein bound (17), and in the present study, it was no longer
detectable in the plasma of newborn macaques within 48 h of
birth.
Studies in humans have shown that maraviroc may have
extended antiviral activity despite being discontinued or unde-
tectable in the blood. A delayed rebound in the viral load in
humans following cessation of treatment was hypothesized to
be due to prolonged occupancy of CCR5 receptors (16). In
results presented here, receptor occupancy on maternal CD4
lymphocytes waned in a temporal relationship with plasma
maraviroc levels. By 48 h after dosing, a proportion of CCR5
receptors were unoccupied when plasma maraviroc concentra-
tions were only slightly above the limit of detection. Evidence of
unoccupied CCR5 receptors suggests CCR5-using HIV could
infect these CD4 lymphocytes. In the infant macaques, our at-
tempts to measure receptor occupancy in the ex vivo assay were
compromised by extremely low CCR5 expression on CD4 lym-
phocytes, which is consistent with extremely low CCR5 expression
(1%) on CD4 lymphocytes in human neonates (6, 33). Indeed,
subsequently analyzed data from other newborn macaques
showed that 0.5 to 2.4% of lymphocytes (12 to 51 cells per l of
blood) express CCR5 receptors in 1- to 3-day-old macaques
(K. K. A. Van Rompay, unpublished data). Nevertheless, given
that CCR5 receptors became unoccupied within 48 h after dosing
in mothers who had plasma maraviroc concentrations that were
44-fold higher than those of the infants, it seems unlikely that
CCR5 receptors on infant CD4 cells remained occupied for any
longer period of time.














Mother A 60 2,830 2 2.9 48 7.2 15,696 18,275
Infant A 99 2 1.0 24 NC 197 235 0.03 0.013
Mother B 60 927 2 14.8 50 18.3 3,479 4,718
Infant B 17 2 2.0 8 NC NC 26 0.02 0.006
Mother C 100 1,022 1.3 12.7 48 21.1 2,970 4,301
Infant C 28 2 2.8 8 NC NC 66 0.03 0.015
Mother D 100 86 1 2.3 48 9.8 577 1,020
Infant D 4 4 3.5 4 NC NC NC 0.04 0.000
Median, mothers 975 2 7.8 48 14.1 3,225 4,510
Median, infants 22 2 2.4 8 NC 197 66 0.03 0.009
a NC, not calculable; AUCT, total area under the time-concentration curve; I/M, infant/mother ratio.
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The work presented here included only a maternal dose of
maraviroc. The current minimum recommended intervention
to reduce MTCT of HIV is a single maternal NVP dose at
delivery plus a single NVP dose to the infant following deliv-
ery. The goal of this study was to determine whether maraviroc
possessed maternal-fetal pharmacokinetic parameters that
were similar to those of NVP (good placental transfer and a
long half-life in the infant). It is possible that alternative ma-
raviroc-based pre- and postpartum protocols, such as infant
dosing with maraviroc or inclusion of additional drugs, such as
ritonavir, to reduce maraviroc clearance, may change the PK
profile and improve the potential efficacy of single-dose mara-
viroc to reduce MTCT.
The results presented here show that a single maternal in-
trapartum dose of maraviroc resulted in low fetal maraviroc
concentrations. While this study included a small number of
macaques, the overall findings were consistent among all ani-
mals. Overall, poor transplacental transfer and a short phar-
macokinetic profile of maraviroc in newborn macaques in this
study suggest that as a sole treatment intervention, a single
intrapartum dose of maraviroc would not be effective in reduc-
ing MTCT of HIV.
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